Belinostat acid

CAS : 866323-87-7

Ref. 3D-RJB32387

Informations sur le produit

• Nom: Belinostat acid
• CAS: 866323-87-7

Description

Belinostat acid is an inorganic compound that has been clinically studied for its potential use in cancer treatment. Belinostat acid is a histone deacetylase inhibitor, which means it prevents the removal of acetyl groups from histones, resulting in gene activation and increased transcription. In vitro studies have shown that belinostat acid can be used to treat cancers by inducing homologous recombination repair and inhibiting cell proliferation. Clinical trials are currently underway to examine the safety and efficacy of this drug as a treatment for solid tumors. The terminal half-life of belinostat acid is about 1 hour, with metabolites being excreted primarily through urine.

Belinostat Acid has been found to inhibit HDACs and other DNA-modifying enzymes such as HATs. It also inhibits the phosphorylation of H3K9, which may play a role in tumorigenesis.
The pharmacokinetics of Belinostat

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 303.3 g/mol
• Formule: C₁₅H₁₃NO₄S
• Degré de pureté: Min. 95%